Allarity Therapeutics, Inc. (ALLR) Stock

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. is led by CEO Thomas H. Jensen, employs 6 people, headquartered in US, publicly traded since 2021.

Allarity Therapeutics, Inc. (ALLR) stock trades at $0.87 with a market capitalization of $13.77M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.33, reflecting a net loss over the last twelve months, price-to-book of 4.68, price-to-sales of 47.96. Over the past 52 weeks the stock has ranged between $0.77 and $1.84, and currently trades 52.7% below its 52-week high.

On profitability, Allarity Therapeutics, Inc. generates a return on equity (ROE) of -152.77% (negative, reflecting a net loss), return on capital employed of -305.29%, an operating margin of -35.53%, a net profit margin of -32.61%.

Allarity Therapeutics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Allarity Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-11.0M.

Operating margin went from -3132.1% in 2016 to -3939.1% in 2025, a fall of 806.9 percentage points. The most recent net margin is -32.61%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-12.0M.

Borrowings stand at $1.0M, cash from operations was $-15.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -172.1% over five years, and was -110.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Allarity Therapeutics, Inc. (ALLR) — frequently asked questions